GVR Report cover Psoriasis Drugs Market Report

Psoriasis Drugs Market Analysis Report by Therapeutic Class (Interleukin-inhibitors, Tumor Necrosis Factor-inhibitors), by Treatment (Topicals, Systemic, Biologics), and Segment Forecasts, 2016 - 2022

  • Report ID: GVR-1-68038-662-2
  • Number of Pages: 115
  • Format: Electronic (PDF)

Industry Insights

The global psoriasis drugs market size was valued at USD 11.3 billion in 2016. It is anticipated to post a CAGR of 9.4% during the forecast period. Increasing awareness regarding treatment and rising demand for improved healthcare infrastructure are among the primary growth stimulants for the market.

Psoriasis is a genetic condition that may not be present at birth. The condition may be triggered by certain environmental and genetic factors. Changing lifestyles of people are leading to increased alcohol consumption and smoking, an unhealthy diet, and sedentary living, which makes people more prone to this condition.

U.S. psoriasis drugs market

Findings of the International Federation of Psoriasis Association indicate that about 5.0% of people suffer from one or more forms of psoriasis across the globe. Nearly 7.5 million people are affected by this condition in the U.S. alone. These patients represent approximately 2.0% of the population. Moreover, approximately 100,000 new cases are registered and reported every year.

Plaque psoriasis is the leading one among the different forms, with more than four-fifths of total patient base suffering at a global level. Guttate psoriasis is the second most prevalent form, affecting approximately 10.0% of patients. Erythrodermic psoriasis is the rarest but the most dangerous type. This condition demands a medical emergency, often leading to hospitalization of patients.

Therapeutic Class Insights

The market has been divided into tumor necrosis factor (TNF)-inhibitors, interleukin inhibitors, and others. TNF inhibitors were the leading therapeutic class in the psoriasis drugs market in 2016. However, they are likely to lose shares over the forecast. The marketed TNF-inhibitors used for psoriasis are Humira (adalimumab), Enbrel (etanercept), Remicade (infliximab), and Cimzia (certolizumab pegol).

Interleukin (IL) inhibitors are expected to witness the fastest growth over the forecast period due to their improved safety and efficacy profiles and rising adoption among end users. Cosentyx (secukinumab), Taltz (ixekizumab), Stelara (ustekinumab), Siliq (brodalumab), Tremfya (guselkumab), and Ilumya (tildrakizumab) are approved as interleukin inhibitors for psoriasis.

The need for efficient and long-lasting drugs is a key driver pushing the market growth. The IL-mode of therapy is beneficial to patients who are intolerant or contraindicated to TNF-α inhibitor therapy. The rising adoption of IL-inhibitor therapy and patent expiries of major TNF-inhibitor drugs such as Humira and Remicade are some of the contributing factors for declining TNF-inhibitor shares in the psoriasis therapeutic space.

Treatment Insights

Psoriasis treatment has been divided into topicals, systemic, and biologics. Biologics led the psoriasis treatment landscape in 2016 due to their targeted action and will continue to dominate the market throughout the forecast horizon. Biologics differ from traditional systemic drugs by targeting specific areas of the immune system.

Topicals are usually the first line of treatment of psoriasis. Topical treatments are further divided into OTC drugs, steroids, and non-steroids. Topical treatments may be used individually or in combination with other therapies for better results. Systemic drugs can be used when topical treatment fails or the patient is unresponsive. However, systemic treatments can have severe side effects.

Regional Insights

The U.S. is expected to dominate the market throughout the forecast horizon. The U.S. held over a 38.0% share in the market in 2016. Established healthcare infrastructure, high adoption of therapeutics, and the presence of key manufacturers in the country are among the primary factors behind its dominance. Moreover, increasing prevalence of psoriasis and favorable government initiatives are providing a boost to the growth of the market.

Global psoriasis drugs market

Japan is estimated to witness the fastest growth over the forecast period with a CAGR of around 13.0% due to the high unmet clinical needs of patients, rising disposable income, growing awareness about early diagnosis, and easy accessibility to quality treatment.

Psoriasis Drugs Market Share Insights

Some of the key players operating in this market are AbbVie Inc.; Amgen Inc.; Johnson & Johnson; Novartis AG; Eli Lilly & Company; AstraZeneca; Celgene Corporation; UCB; and Merck. Several companies, such as Boehringer Ingelheim and LEO Pharma, are emerging as promising players in the market.

Companies are focused on business expansion in developing regions or emerging markets such as India, China, and South Korea, by adopting strategies including alliances and acquisitions for the development of novel products. The emergence of biosimilars is also a trend that is being increasingly adopted by these companies.

Report Scope



Base year for estimation


Forecast period

2017 - 2022

Market representation

Revenue in USD Million & CAGR from 2016 to 2022

Country scope

U.S., U.K., Germany, Spain, Italy, France, Japan

Report coverage

Revenue forecast, company share, competitive landscape, growth factors and trends

15% free customization scope (equivalent to 5 analyst working days)

If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization

Segments Covered in the Report

This report forecasts revenue growth at the global, regional, & country levels and provides an analysis of industry trends in each of the sub-segments over the forecast period. For the purpose of the study, Grand View Research has segmented the global automotive NGV market report on the basis of fuel type, vehicle type, and region:

  • Therapeutic Class Outlook (Revenue, USD Million, 2016 - 2022)

    • Tumor Necrosis Factor Inhibitor

    • Interleukin Inhibitors

    • Others

  • Treatment Outlook (Revenue, USD Million, 2016 - 2022)

    • Topicals

    • Systemic

    • Biologics

  • Regional Outlook (Revenue, USD Million, 2016 - 2022)

    • The U.S.

    • The U.K.

    • Germany

    • Spain

    • France

    • Italy

    • Japan

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.